Education
About Us
Working with TipRanks
Follow Us
Calidi Biotherapeutics (CLDI)
:CLDI
Total Valuation
Calidi Biotherapeutics has a market cap or net worth of $15.75M. The enterprise value is $21.65M.
Market Cap$15.75M
Enterprise Value$21.65M
Share Statistics
Calidi Biotherapeutics has 33,592,580 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding33,592,580
Owned by Insiders3.44%
Owned by Institutions0.33%
Financial Efficiency
Calidi Biotherapeutics’s return on equity (ROE) is 3.55 and return on invested capital (ROIC) is -1696.37%.
Return on Equity (ROE)3.55
Return on Assets (ROA)-2.92
Return on Invested Capital (ROIC)-1696.37%
Return on Capital Employed (ROCE)136.11
Revenue Per Employee0.00
Profits Per Employee-1.04M
Employee Count28
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Calidi Biotherapeutics is -8.73. Calidi Biotherapeutics’s PEG ratio is 0.09.
PE Ratio-8.73
PS Ratio―
PB Ratio-30.96
Price to Fair Value-30.96
Price to FCF-9.25
Price to Operating Cash Flow-9.45
PEG Ratio0.09
Income Statement
In the last 12 months, Calidi Biotherapeutics had revenue of 0.00 and earned -29.22M in profits. Earnings per share was -1.73.
Revenue0.00
Gross Profit-1.26M
Operating Income-28.99M
Pretax Income-29.20M
Net Income-29.22M
EBITDA-27.58M
Earnings Per Share (EPS)-1.73
Cash Flow
In the last 12 months, operating cash flow was -31.01M and capital expenditures -896.00K, giving a free cash flow of -31.90M billion.
Operating Cash Flow-31.01M
Free Cash Flow-31.90M
Free Cash Flow per Share-0.95
Dividends & Yields
Calidi Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.07
52-Week Price Change-70.25%
50-Day Moving Average0.79
200-Day Moving Average1.26
Relative Strength Index (RSI)36.86
Average Volume (3m)382.20K
Important Dates
Calidi Biotherapeutics upcoming earnings date is May 20, 2025, TBA Not Confirmed.
Last Earnings DateMar 31, 2025
Next Earnings DateMay 20, 2025
Ex-Dividend Date―
Financial Position
Calidi Biotherapeutics as a current ratio of 0.42, with Debt / Equity ratio of -87.74%
Current Ratio0.42
Quick Ratio0.42
Debt to Market Cap0.01
Net Debt to EBITDA-0.19
Interest Coverage Ratio-27.12
Taxes
In the past 12 months, Calidi Biotherapeutics has paid 16.00K in taxes.
Income Tax16.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Calidi Biotherapeutics EV to EBITDA ratio is -9.43, with an EV/FCF ratio of -9.44.
EV to Sales0.00
EV to EBITDA-9.43
EV to Free Cash Flow-9.44
EV to Operating Cash Flow-9.64
Balance Sheet
Calidi Biotherapeutics has $1.24M in cash and marketable securities with $11.71M in debt, giving a net cash position of $10.47M billion.
Cash & Marketable Securities$1.24M
Total Debt$11.71M
Net Cash$10.47M
Net Cash Per Share$0.31
Tangible Book Value Per Share-$0.49
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Calidi Biotherapeutics is $2.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$2.50
Price Target Upside468.18% Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast64.19%